What is the appropriate dosing, monitoring, and contraindications for diltiazem (Cardizem) in treating ischemic chest pain/angina?

Diltiazem (Cardizem) for Ischemic Chest Pain/Angina

For stable angina, start diltiazem at 120-180 mg once daily (extended-release formulation) and titrate up to 240-360 mg daily based on symptom control, with maximum studied doses of 480-540 mg daily if needed. 1

Dosing Strategy

Initial Dosing

• Stable angina: Start with 120-180 mg once daily of extended-release formulation 1
• Hypertension with angina: Start with 180-240 mg once daily 1
• Maximum antihypertensive effect occurs by 14 days, so adjust dosing accordingly 1

Titration Protocol

The evidence demonstrates clear dose-response relationships. Titrate over 7-14 days based on symptom control 1:

• 240 mg/day reduces anginal attacks by approximately 60% 2
• 360 mg/day provides additional benefit with 67% reduction in attacks 3
• Individual patients may require up to 480 mg daily 1
• Doses up to 540 mg have been studied, though side effects increase with higher doses 1

Special Situations

Unstable angina (intravenous): For acute management, continuous IV infusion is highly effective 4:

• Start at 1 mcg/kg/min (controls 63% of patients)
• Titrate to 3 mcg/kg/min if needed (additional 25% controlled)
• Maximum 5 mcg/kg/min (cumulative 94% effectiveness)
• Maintain at angina-free dose for 48 hours 4

Vasospastic angina: Diltiazem is particularly effective, reducing attack frequency by 94% at 240-360 mg daily 5. This is a preferred indication per current guidelines 6.

Monitoring Parameters

Heart Rate Targets

• Target resting heart rate: 55-60 bpm when used for antianginal purposes 6
• Diltiazem has a "regulating effect" - it reduces tachycardia (HR >85 bpm) without causing excessive bradycardia at baseline HR <74 bpm 7
• Monitor for first-degree AV block, which shows strongest dose relationship 1

Hemodynamic Monitoring

• Blood pressure (expect modest reduction in normotensive patients) 1
• Watch for PR interval prolongation (average 14% increase at 300 mg dose) 1
• Assess for peripheral edema (trace to 1+ occurs in some patients) 5

Efficacy Assessment

• Reassess response to therapy and adjust if inadequate angina control or poor tolerance 6
• Treadmill exercise time should improve by 90-100 seconds at therapeutic doses 1
• Weekly anginal frequency should decrease by 60-70% 2, 3

Contraindications and Critical Warnings

Absolute Contraindications

• Sick sinus syndrome (diltiazem significantly prolongs sinus cycle length up to 50%) 1
• Second- or third-degree AV block (unless pacemaker present)
• Heart failure with reduced ejection fraction (HFrEF) 6 - this is explicitly contraindicated per current guidelines
• Severe hypotension

Important Cautions

• Patients with first-degree AV block: Diltiazem prolongs AH interval by ~20% 1
• Hepatic impairment: 69% increase in bioavailability and prolonged half-life in cirrhosis 1 - reduce initial dose
• Combination with beta-blockers: Use caution, particularly in patients with poor ventricular function 6, 1. However, this combination can be used in specific situations like atrial fibrillation 6

Drug Interactions

• Safe coadministration: Sublingual nitroglycerin, long-acting nitrates, other antihypertensives (may need dose adjustment) 1
• Hepatic enzyme interactions: Drugs that induce/inhibit hepatic microsomal enzymes may alter diltiazem levels 1
• Plasma protein binding 70-80%, but not altered by digoxin, warfarin, propranolol at therapeutic concentrations 1

Guideline Context

The 2024 ESC guidelines position diltiazem as a first-line option for specific angina types 6:

• Particularly indicated for vasospastic angina (where it's preferred over beta-blockers)
• Useful in obstructive CAD when beta-blockers are contraindicated or not tolerated
• Can be combined with beta-blockers in atrial fibrillation
• Avoid in HFrEF - this is a critical contraindication

The non-dihydropyridine calcium channel blockers (diltiazem/verapamil) differ fundamentally from dihydropyridines by lowering rather than increasing heart rate, which may translate to better outcomes in acute cardiovascular conditions 7.

Common Pitfalls

• Don't underdose: Many patients, especially those on hemodialysis, receive inadequate doses due to excessive caution 8. The optimal dose is often 240 mg/day sustained-release formulation.
• Don't use in HFrEF: This is explicitly contraindicated despite diltiazem's negative inotropic effects being mild 6
• Monitor for bradyarrhythmias: These occur in ~6% of patients but are reversible with dose reduction 4
• Incidence of side effects increases with dose: First-degree AV block, dizziness, and sinus bradycardia show strongest dose relationships 1